These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 25777337

  • 1. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
    Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gómez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D.
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1301-8. PubMed ID: 25777337
    [Abstract] [Full Text] [Related]

  • 2. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [Abstract] [Full Text] [Related]

  • 3. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E, Aghemo A, Colombo M.
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection.
    Ikezawa K, Naito M, Yumiba T, Iwahashi K, Onishi Y, Kita H, Nishio A, Kanno T, Matsuura T, Ono A, Chiba M, Mizuno T, Aketa H, Maeda K, Michida T, Katayama K.
    J Viral Hepat; 2010 Jul; 17(7):488-92. PubMed ID: 19840366
    [Abstract] [Full Text] [Related]

  • 8. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL, Ehleben C, Perrys M.
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [Abstract] [Full Text] [Related]

  • 9. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
    Bruno S, Sewpaul P, Russo ML, Boccaccio V, Almasio PL, Giannini EG.
    Dig Liver Dis; 2015 Oct; 47(10):864-8. PubMed ID: 26187555
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].
    Yu JW, Sun LJ, Kang P, Zhao YH, Yan BZ, Zhu PF.
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1002-7. PubMed ID: 22333166
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ.
    N Engl J Med; 2013 May 16; 368(20):1878-87. PubMed ID: 23607594
    [Abstract] [Full Text] [Related]

  • 15. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.
    Giannini EG, Marenco S, Fazio V, Pieri G, Savarino V, Picciotto A.
    Liver Int; 2012 Aug 16; 32(7):1113-9. PubMed ID: 22471814
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T.
    J Med Virol; 2015 Jul 16; 87(7):1199-206. PubMed ID: 25772024
    [Abstract] [Full Text] [Related]

  • 20. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.
    Gastroenterology; 2015 Feb 16; 148(2):355-366.e1. PubMed ID: 25311593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.